Titan Pharmaceuticals IncNASDAQ:TTNP
- LAST PRICE1.5200
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.5200/ 5
- Ask / Lots1.5500/ 3
- Open / Previous Close0.0000 / 1.5200
- Day Range---
- 52 Week Range
- Volume495
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TTNP |
|---|---|---|
| 09:32 ET | 5159 | 1.53 |
| 09:41 ET | 300 | 1.555 |
| 09:43 ET | 3792 | 1.565 |
| 09:48 ET | 1500 | 1.555 |
| 10:08 ET | 8660 | 1.54 |
| 10:14 ET | 100 | 1.55 |
| 10:17 ET | 200 | 1.54 |
| 10:26 ET | 100 | 1.59 |
| 10:32 ET | 100 | 1.56 |
| 10:37 ET | 990 | 1.56 |
| 10:39 ET | 200 | 1.53 |
| 10:44 ET | 1384 | 1.53 |
| 10:46 ET | 100 | 1.58 |
| 10:48 ET | 100 | 1.58 |
| 10:53 ET | 782 | 1.53 |
| 10:55 ET | 700 | 1.54 |
| 11:00 ET | 5955 | 1.54 |
| 11:06 ET | 3100 | 1.53 |
| 11:20 ET | 1201 | 1.51 |
| 11:22 ET | 2143 | 1.51 |
| 11:26 ET | 666 | 1.525 |
| 11:29 ET | 150 | 1.5185 |
| 11:40 ET | 666 | 1.5314 |
| 11:42 ET | 100 | 1.51 |
| 11:49 ET | 200 | 1.53 |
| 12:03 ET | 100 | 1.52 |
| 12:05 ET | 200 | 1.52 |
| 12:14 ET | 687 | 1.52 |
| 12:21 ET | 10664 | 1.53 |
| 12:27 ET | 5820 | 1.54 |
| 12:52 ET | 200 | 1.55 |
| 01:03 ET | 500 | 1.5381 |
| 01:06 ET | 500 | 1.5213 |
| 01:12 ET | 100 | 1.53 |
| 01:24 ET | 975 | 1.5212 |
| 01:33 ET | 370 | 1.53 |
| 01:35 ET | 100 | 1.53 |
| 01:42 ET | 107 | 1.5219 |
| 01:50 ET | 300 | 1.54 |
| 01:53 ET | 100 | 1.53 |
| 02:09 ET | 1730 | 1.53 |
| 02:11 ET | 267 | 1.5215 |
| 02:51 ET | 100 | 1.53 |
| 02:54 ET | 200 | 1.5267 |
| 03:00 ET | 4070 | 1.52 |
| 03:12 ET | 900 | 1.53 |
| 03:14 ET | 100 | 1.52 |
| 03:16 ET | 512 | 1.52 |
| 03:18 ET | 200 | 1.5201 |
| 03:21 ET | 843 | 1.52 |
| 03:23 ET | 111 | 1.52 |
| 03:27 ET | 100 | 1.52 |
| 03:32 ET | 100 | 1.52 |
| 03:36 ET | 167 | 1.52 |
| 03:39 ET | 893 | 1.52 |
| 03:41 ET | 200 | 1.52 |
| 03:43 ET | 245 | 1.52 |
| 03:45 ET | 537 | 1.52 |
| 03:48 ET | 199 | 1.52 |
| 03:54 ET | 224 | 1.52 |
| 03:56 ET | 2048 | 1.52 |
| 03:57 ET | 147 | 1.52 |
| 03:59 ET | 780 | 1.52 |
Aug 16, 2022
BRIEF-Titan Pharmaceuticals Announces Board Expansion And Management Changes, from 1:50PM ET on Tuesday Aug 16, 2022 by Thomson Reuters
1:50PM ET on Tuesday Aug 16, 2022 by Thomson ReutersTitan Pharmaceuticals Appoints David E. Lazar Interim Chairman, CEO; Expands Board After Election of Director Nominees, from 11:23AM ET on Tuesday Aug 16, 2022 by MT Newswires
11:23AM ET on Tuesday Aug 16, 2022 by MT NewswiresTitan Pharmaceuticals Announces Board Expansion and Management Changes, from 10:53AM ET on Tuesday Aug 16, 2022 by PR Newswire
10:53AM ET on Tuesday Aug 16, 2022 by PR Newswire
Jul 22, 2022
BRIEF-Titan Pharma Received Confirmation From Nasdaq That Co Has Regained Compliance , from 4:40PM ET on Friday Jul 22, 2022 by Thomson Reuters
4:40PM ET on Friday Jul 22, 2022 by Thomson ReutersTitan Pharmaceuticals Regains Nasdaq Compliance With Minimum Bid Price Requirement, from 4:13PM ET on Friday Jul 22, 2022 by MT Newswires
4:13PM ET on Friday Jul 22, 2022 by MT Newswires
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Titan Pharmaceuticals Inc | 19.0M | -1.8x | --- |
Cyclo Therapeutics Inc | 18.9M | -1.4x | --- |
Winston Pharmaceuticals Inc | 23.2M | -8.2x | --- |
Endexx Corp | 22.5M | -2.6x | --- |
Lexaria Bioscience Corp | 17.1M | -2.4x | --- |
Sonnet Biotherapeutics Holdings Inc | 17.6M | -0.4x | --- |
Company Information
Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing therapeutics using its long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. Its ProNeura continuous drug delivery system consists of a small, solid rod-shaped implant made from a mixture of ethylene-vinyl acetate (EVA), and a drug substance. Its product Probuphine (buprenorphine implant), is based on ProNeura technology, which is used for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 milligrams (mg) or less a day of oral buprenorphine. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant and Nalmefene Implant. Its TP-2021 is used for the treatment of moderate-to-severe chronic pruritus. Its Nalmefene Implant is used for the prevention of relapse in opioid use disorder (OUD) patients following detoxification from opioids.
Contact Information
- Headquarters
- SUITE 505, 400 OYSTER POINT BLVDSAN FRANCISCO, CA, United States 94080
- Phone
- 415-244-4990
- Fax
- 650-244-4956
Executives
- Interim Chairman of the Board, Chief Executive Officer
- David Lazar
- President, Chief Operating Officer, Director
- Katherine DeVarney
- Director
- Avraham Ben-Tzvi
- Director
- Peter Chasey
- Director
- Eric Greenberg
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $19.0M |
|---|---|
Revenue (TTM) | $1.0M |
Shares Outstanding | 14.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.19 |
EPS | $-0.86 |
Book Value | $0.52 |
P/E Ratio | -1.8x |
Price/Sales (TTM) | 18.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -830.12% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
